XTX Topco Ltd Grows Position in Axon Enterprise, Inc. (NASDAQ:AXON)

XTX Topco Ltd grew its stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 14.5% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,686 shares of the biotechnology company’s stock after buying an additional 593 shares during the period. XTX Topco Ltd’s holdings in Axon Enterprise were worth $1,379,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in the stock. 9258 Wealth Management LLC acquired a new position in Axon Enterprise in the 4th quarter valued at about $204,000. Principal Securities Inc. purchased a new position in shares of Axon Enterprise during the fourth quarter valued at approximately $49,000. Beacon Pointe Advisors LLC acquired a new stake in Axon Enterprise during the fourth quarter worth approximately $218,000. Robeco Institutional Asset Management B.V. boosted its position in Axon Enterprise by 1,049.8% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 59,319 shares of the biotechnology company’s stock worth $153,000 after acquiring an additional 54,160 shares during the last quarter. Finally, PNC Financial Services Group Inc. grew its stake in Axon Enterprise by 11.0% in the 4th quarter. PNC Financial Services Group Inc. now owns 4,320 shares of the biotechnology company’s stock worth $1,116,000 after acquiring an additional 427 shares during the period. 79.08% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on AXON shares. Craig Hallum raised their price objective on Axon Enterprise from $370.00 to $376.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Bank of America began coverage on Axon Enterprise in a research note on Wednesday, July 17th. They issued a “buy” rating and a $380.00 price target on the stock. Jefferies Financial Group began coverage on shares of Axon Enterprise in a report on Wednesday, July 17th. They set a “buy” rating and a $385.00 price objective on the stock. Northland Securities raised their target price on shares of Axon Enterprise from $330.00 to $365.00 and gave the stock an “outperform” rating in a research report on Thursday, August 8th. Finally, Barclays upped their price target on shares of Axon Enterprise from $381.00 to $387.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $365.38.

Axon Enterprise Stock Up 0.9 %

Shares of Axon Enterprise stock opened at $393.29 on Friday. The company has a fifty day moving average price of $348.04 and a 200 day moving average price of $317.21. The company has a current ratio of 2.88, a quick ratio of 2.52 and a debt-to-equity ratio of 0.35. Axon Enterprise, Inc. has a twelve month low of $189.12 and a twelve month high of $393.58. The stock has a market cap of $29.72 billion, a price-to-earnings ratio of 115.00, a price-to-earnings-growth ratio of 10.34 and a beta of 0.94.

Axon Enterprise (NASDAQ:AXON) last issued its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.18. The company had revenue of $504.00 million during the quarter, compared to the consensus estimate of $478.35 million. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The company’s revenue was up 34.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.80 earnings per share. Equities research analysts forecast that Axon Enterprise, Inc. will post 1.79 earnings per share for the current fiscal year.

Insider Buying and Selling at Axon Enterprise

In other news, Director Caitlin Elizabeth Kalinowski sold 450 shares of the company’s stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $373.03, for a total value of $167,863.50. Following the completion of the transaction, the director now directly owns 7,379 shares in the company, valued at $2,752,588.37. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Caitlin Elizabeth Kalinowski sold 450 shares of the business’s stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $373.03, for a total value of $167,863.50. Following the transaction, the director now owns 7,379 shares in the company, valued at $2,752,588.37. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Matthew R. Mcbrady sold 2,000 shares of the stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $364.66, for a total value of $729,320.00. Following the completion of the transaction, the director now directly owns 4,892 shares of the company’s stock, valued at approximately $1,783,916.72. The disclosure for this sale can be found here. Insiders sold 317,981 shares of company stock valued at $115,662,734 over the last 90 days. 6.10% of the stock is owned by corporate insiders.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.